Effect of fluconazole on the pharmacokinetics of doxorubicin in nonhuman primates

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 4, 2000, Pages 1100-1101

  Warren, Katherine E ^a,b   McCully, Cynthia M ^a   Walsh, Thomas J ^a   Balis, Frank M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Pediatric Oncology Branch   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DOXORUBICIN; FLUCONAZOLE; KETOCONAZOLE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; MALE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; RHESUS MONKEY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOXORUBICIN; DRUG INTERACTIONS; FLUCONAZOLE; HALF-LIFE; INJECTIONS, INTRAVENOUS; MACACA MULATTA; MALE; SPECTROMETRY, FLUORESCENCE;

EID: 0034021524     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.4.1100-1101.2000     Document Type: Article

References (15)

1. Albengres, E., H. Le Louet, and J. P. Tillement. 1998. Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf. 18:83-97.
2. Arndt, C. A. S., T. J. Walsh, F. M. Balis, P. A. Pizzo, and D. G. Poplack. 1988. Cerebrospinal fluid penetration of fluconazole: implications for antifungal therapy in patients with acquired immunodeficiency syndrome. J. Infect. Dis. 157:178-180.
3. Debruyne, D., and J. P. Ryckelynck. 1993. Clinical pharmacokinetics of fluconazole. Clin. Pharmacokinet. 24:10-27.
4. Goodman, J. L., D. J. Winston, R. A. Greenfield, P. H. Chandrasekar, B. Fox, H. Kaizer, R. K. Shadduck, T. C. Shea, P. Stiff, D. J. Friedman, et al. 1992. A controlled trial of fluconazole to prevent fungal infections in patients undergoing hone marrow transplantation. N. Engl. J. Med. 326:845-851.
5. Greene, R. F., J. M. Collins, J. F. Jenkins, et al. 1983. Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer Res. 43:3417-3421.
6. Harris, N. L., D. E. Brenner, L. B. Anthony, J. C. Collins, S. Halter, and K. R. Hande. 1988. The influence of ranitidine on the pharmacokinetics and toxicity of doxorubicin in rabbits. Cancer Chemother. Pharmacol. 21:323-328.
7. McCully, C. L., F. M. Balis, J. Bacher, J. Phillips, and D. G. Poplack. 1990. A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid. Lab. Anim. Sci. 40:250-255.
8. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, D.C.
9. Palmblad, J., B. Lonnqvist, B. Carlsson, G. Grimfors, M. Jarnmark, R. Lerner, P. Ljungman, C. Nystrom-Rosander, B. Petrini, and G. Oberg. 1992. Oral ketoconazole prophylaxis for Candida infections during induction therapy for acute leukaemia in adults: more bacteraemias. J. Intern. Med. 231: 363-370.
10. Reich, S. D., and N. R. Bachur. 1976. Alterations in adriamycin efficacy by phenobarbital. Cancer Res. 36:3803-3806.
11. Robert, J. 1998. Anthracyclines, p. 96-173. In L. B. Grochow and M. M. Ames (ed.), a clinician's guide to chemotherapy pharmacokinetics and pharmacodynamics, 1st ed. The Williams & Wilkins Co., Baltimore, Md.
12. Schaffner, A., and M. Schaffner. 1995. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J. Infect. Dis. 172:1035-1041.
13. Speth, P. A. J., Q. G. C. M. van Hoesel, and C. Haanen. 1988. Clinical pharmacokinetics of doxorubicin. Clin. Pharmacokinet. 15:15-31.
14. Swerdloff, J. N., S. G. Filler, and J. E. Edwards, Jr. 1993. Severe candidal infections in neutropenic patients. Clin. Infect. Dis. 17(Suppl. 2):S457-S467.
15. Walsh, T. J., and J. W. Lee. 1993. Prevention of invasive fungal infections in patients with neoplastic disease. Clin. Infect. Dis. 17(Suppl. 2):S468-S480.